Human SUMO1 MAb (Clone 852620)

Applications

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Preparation and Storage

Background: SUMO1

Small Ubiquitin­like Modifiers (SUMOs) are a family of small, related proteins that can be enzymatically attached to a target protein by a post­translational modification process termed SUMOylation. Unlike ubiquitination, which targets proteins for degradation, SUMOylation participates in a number of cellular processes, such as nuclear transport, transcriptional regulation, apoptosis, and protein stability. All human SUMO proteins share a conserved ubiquitin-like domain and a C-terminal diglycine cleavage/attachment site. Human SUMO1, also known as Sentrin, UBL1, and SMT3C, is synthesized as a 101 amino acid (aa) propeptide that contains a four aa C­terminal prosegment. Following prosegment cleavage, the C­terminal glycine may be enzymatically attached to a lysine on a target protein. Human SUMO1 shares 100% sequence identity to SUMO1 from mouse. SUMO1 is the most unique of the four identified SUMO proteins and shares only 44%, 47%, and 41% sequence identity to SUMO2, SUMO3, and SUMO4, respectively.

Product Datasheets

Related Research Areas

• NFkB Pathway
• Ubiquitin-like Modifiers (UBLs) and Regulators